Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.
J Exp Clin Cancer Res. 2023 Jul 18;42(1):171. doi: 10.1186/s13046-023-02724-y.
Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are established cancer treatment modalities that are widely used due to their demonstrated efficacy against tumors and favorable safety profiles or tolerability. Nevertheless, treatment resistance continues to be one of the most pressing unsolved conundrums in cancer treatment. Hypoxia-inducible factors (HIFs) are a family of transcription factors that regulate cellular responses to hypoxia by activating genes involved in various adaptations, including erythropoiesis, glucose metabolism, angiogenesis, cell proliferation, and apoptosis. Despite this critical function, overexpression of HIFs has been observed in numerous cancers, leading to resistance to therapy and disease progression. In recent years, much effort has been poured into developing innovative cancer treatments that target the HIF pathway. Combining HIF inhibitors with current cancer therapies to increase anti-tumor activity and diminish treatment resistance is one strategy for combating therapeutic resistance. This review focuses on how HIF inhibitors could be applied in conjunction with current cancer treatments, including those now being evaluated in clinical trials, to usher in a new era of cancer therapy.
化疗、放疗、靶向治疗和免疫疗法是已确立的癌症治疗方式，由于它们对肿瘤的疗效显著且安全性或耐受性良好，因此被广泛应用。然而，治疗耐药性仍然是癌症治疗中最紧迫的未解难题之一。缺氧诱导因子（HIFs）是一组转录因子，通过激活涉及各种适应的基因（包括红细胞生成、葡萄糖代谢、血管生成、细胞增殖和细胞凋亡）来调节细胞对缺氧的反应。尽管具有这种关键功能，但在许多癌症中观察到 HIFs 的过度表达，导致对治疗和疾病进展的耐药性。近年来，人们投入大量精力开发针对 HIF 途径的创新癌症治疗方法。将 HIF 抑制剂与当前的癌症治疗方法结合使用以提高抗肿瘤活性并减少治疗耐药性是对抗治疗耐药性的一种策略。这篇综述重点介绍了如何将 HIF 抑制剂与当前的癌症治疗方法（包括正在临床试验中评估的方法）结合使用，以开创癌症治疗的新时代。
